NEPH

Business Context and Reporting Period

Company: Nephros, Inc. (NEPH)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Nephros develops and markets high-performance water filtration solutions for medical (infection control, dialysis) and commercial applications. The company operates as a single reporting segment and is classified as a smaller reporting company.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2026): Net cash used in operating activities was $(990) thousand, compared to net cash provided of $1,316 thousand in the prior year period. This shift was driven by increases in accounts receivable ($1.7M) and inventory ($1.3M), offsetting net income and an increase in accounts payable.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 36% in Q2 2026 and 21% YTD 2026 compared to 2025. Growth was driven by programmatic product sales and service revenue, though emergency response revenue declined YTD compared to the prior year.
• Profitability Surge: Net income increased 405% in Q2 and 68% YTD. This was significantly boosted by a one-time benefit from IEEPA tariff refunds.
• Tariff Refund Impact: The company recognized a $624,000 reduction in Cost of Goods Sold (COGS) related to IEEPA tariff refunds approved by the U.S. Customs and Border Protection. Approximately $647,000 is recorded as a receivable as cash had not been collected by period end.
• Expense Increases: SG&A expenses rose 10% in Q2 and 11% YTD due to increased headcount and sales commissions. R&D expenses increased 18% in Q2 and 17% YTD due to higher salary expenses.
• Liquidity: Cash balances decreased from $5.4M to $4.7M during the six-month period due to working capital build-up (inventory and receivables).

Guidance, Outlook, and Risks

Management Commentary: Management believes existing cash balances and projected cash flows are sufficient to fund operations for at least the next 12 months. The company continues to focus on sales growth and expense management to sustain positive cash flow.

Outlook & Risks:

• Tariff Environment: While IEEPA tariffs were invalidated, new tariffs under other statutory bases remain in effect. Management expects gross margins to continue facing headwinds from current U.S. tariff policies.
• Customer Concentration: For the three months ended June 30, 2026, four major customers accounted for 56% of total revenue. Customer "A" alone represented 27% of revenue.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to revenue recognition for contracts with multiple performance obligations (products and services). Remediation efforts were implemented by September 30, 2025, but the weakness was not considered fully remediated as of June 30, 2026.
• Supply Chain: The company has a minimum purchase commitment with its sole supplier of filter material (Medica S.p.A.) through 2030. Failure to meet these commitments could result in breach of contract.

Investor Verification Checklist

• Tariff Refund Realization: Verify the actual receipt of the $647,000 IEEPA tariff refund receivable and any associated statutory interest.
• Revenue Quality: Assess the sustainability of revenue growth given the decline in emergency response business and the one-time nature of the tariff refund benefit on margins.
• Working Capital Trends: Monitor the continued build-up of accounts receivable and inventory, which drove negative operating cash flow despite profitability.
• Internal Control Remediation: Confirm the timeline for the full remediation of the material weakness regarding revenue recognition controls.
• Customer Concentration: Evaluate the risk associated with reliance on top customers, particularly Customer "A" (27% of Q2 revenue).